AMIX (Autonomix Medical) Additional Paid-In Capital: $72.98 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $5.27
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical Additional Paid-In Capital?

Autonomix Medical AMIX +1.54% 15 Additional Paid-In Capital is $72.98 Mil as of Jun. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.


Autonomix Medical's quarterly additional paid-in capital increased from Dec. 2025 ($72.98 Mil) to Mar. 2026 ($72.98 Mil) and increased from Mar. 2026 ($72.98 Mil) to Jun. 2026 ($72.98 Mil).

Autonomix Medical's annual additional paid-in capital increased from Mar. 2024 ($46.60 Mil) to Mar. 2025 ($58.48 Mil) and increased from Mar. 2025 ($58.48 Mil) to Mar. 2026 ($72.98 Mil).

Autonomix Medical Additional Paid-In Capital Related Terms

Autonomix Medical Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical Additional Paid-In Capital Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Additional Paid-In Capital
24.18 46.60 58.48 72.98

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.74 67.61 72.98 72.98 72.98
AMIX
15GF Score
Autonomix Medical Inc AMIX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $72.98 Mil mean?
Autonomix Medical (AMIX) has a Additional Paid-In Capital of $72.98 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Autonomix Medical and its competitors.
Is Autonomix Medical's Additional Paid-In Capital too high?
Autonomix Medical's current Additional Paid-In Capital is $72.98 Mil. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Additional Paid-In Capital compare to AEMD and NUMD?
Autonomix Medical's Additional Paid-In Capital of $72.98 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Autonomix Medical and its competitors. Autonomix Medical's current Additional Paid-In Capital is $72.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Additional Paid-In Capital of $72.98 Mil. The current Additional Paid-In Capital is $72.98 Mil. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Additional Paid-In Capital is $72.98 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.27
Price